Allergan's Botox receives complete response letter for upper limb spasticity
This article was originally published in Scrip
Executive Summary
The US FDA has issued a complete response letter to Allergan for its supplemental BLA on its botulinum Type A product, Botox, for the treatment of upper limb spasticity in stroke patients.